We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
Merck (MRK - Free Report) closed at $123.54 in the latest trading session, marking a -1.22% move from the prior day. This change lagged the S&P 500's 0.42% gain on the day. Meanwhile, the Dow gained 0.29%, and the Nasdaq, a tech-heavy index, added 0.29%.
Shares of the pharmaceutical company have appreciated by 3.57% over the course of the past month, underperforming the Medical sector's gain of 5.6%, and outperforming the S&P 500's gain of 2.2%.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on August 4, 2026. The company's earnings per share (EPS) are projected to be $2.15, reflecting a 0.94% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $16.3 billion, reflecting a 3.13% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.17 per share and a revenue of $66.76 billion, signifying shifts of -42.43% and +2.7%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.03% fall in the Zacks Consensus EPS estimate. Right now, Merck possesses a Zacks Rank of #3 (Hold).
With respect to valuation, Merck is currently being traded at a Forward P/E ratio of 24.21. For comparison, its industry has an average Forward P/E of 16.45, which means Merck is trading at a premium to the group.
Also, we should mention that MRK has a PEG ratio of 2.68. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.66.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 178, finds itself in the bottom 28% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Stock Sinks As Market Gains: Here's Why
Merck (MRK - Free Report) closed at $123.54 in the latest trading session, marking a -1.22% move from the prior day. This change lagged the S&P 500's 0.42% gain on the day. Meanwhile, the Dow gained 0.29%, and the Nasdaq, a tech-heavy index, added 0.29%.
Shares of the pharmaceutical company have appreciated by 3.57% over the course of the past month, underperforming the Medical sector's gain of 5.6%, and outperforming the S&P 500's gain of 2.2%.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on August 4, 2026. The company's earnings per share (EPS) are projected to be $2.15, reflecting a 0.94% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $16.3 billion, reflecting a 3.13% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.17 per share and a revenue of $66.76 billion, signifying shifts of -42.43% and +2.7%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.03% fall in the Zacks Consensus EPS estimate. Right now, Merck possesses a Zacks Rank of #3 (Hold).
With respect to valuation, Merck is currently being traded at a Forward P/E ratio of 24.21. For comparison, its industry has an average Forward P/E of 16.45, which means Merck is trading at a premium to the group.
Also, we should mention that MRK has a PEG ratio of 2.68. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.66.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 178, finds itself in the bottom 28% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.